827599-20-2

Basic information

• Product Name: 3-tert-butyl 6-ethyl (1R*,5S*,6S*)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate
• CAS NO: 827599-20-2
• Molecular Weight: 255.314
• Mol File: 827599-20-2.mol

Chemical Properties

• CAS DataBase Reference: 3-tert-butyl 6-ethyl (1R*,5S*,6S*)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-tert-butyl 6-ethyl (1R*,5S*,6S*)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate(827599-20-2)
• EPA Substance Registry System: 3-tert-butyl 6-ethyl (1R*,5S*,6S*)-3-azabicyclo[3.1.0]hexane-3,6-dicarboxylate(827599-20-2)

Safety Data

• Hazardous Substances Data: 827599-20-2(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 623-73-4 diazoacetic acid ethyl ester 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 

Downstream Products

• 1119512-39-8 rac-(1R,5S,6r)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-6-carboxylic acid 
• 827599-21-3 (1R,5S,6s)-3-tert-butyl 6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-6-carboxylatye 

Relevant articles and documents

QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE

The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).

NOVEL 6-PYRAZOLYLAMIDO-3-SUBSTITUTED AZABICYCLO[3.1.0]HEXANE COMPOUNDS AS CALCIUM CHANNEL INHIBITORS

The present invention relates to a 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane derivatives useful as calcium channel blockers, pharmaceutically acceptable salts thereof and medical use of the calcium channel inhibiting effect of the compounds for treatment of diseases.

Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex- 6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists

A novel class of small molecule NPY Y5 antagonists based around an azabicyclo[3.1.0]hexane scaffold was identified through modification of a screening hit. Structure-activity relationships and efforts undertaken to achieve a favourable pharmacokinetic profile in rat are described.